| Copper in the human organism M Angelova, S Asenova, V Nedkova, R Koleva-Kolarova Trakia journal of sciences 9 (1), 88-98, 2011 | 222 | 2011 |
| The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients RG Koleva-Kolarova, MJW Greuter, M Van Kruchten, KM Vermeulen, ... British Journal of Cancer 112 (10), 1617-1625, 2015 | 46* | 2015 |
| Simulation models in population breast cancer screening: a systematic review RG Koleva-Kolarova, Z Zhan, MJW Greuter, TL Feenstra, GH De Bock The Breast 24 (4), 354-363, 2015 | 35 | 2015 |
| Large expert-curated database for benchmarking document similarity detection in biomedical literature search P Brown, AC Tan, MA El-Esawi, T Liehr, O Blanck, DP Gladue, ... Database 2019, 2019 | 34 | 2019 |
| Guidance for the harmonisation and improvement of economic evaluations of personalised medicine H Vellekoop, S Huygens, M Versteegh, L Szilberhorn, T Zelei, B Nagy, ... Pharmacoeconomics 39 (7), 771-788, 2021 | 32 | 2021 |
| Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis RG Koleva-Kolarova, MP Oktora, AL Robijn, MJW Greuter, AKL Reyners, ... Cancer Treatment Reviews 55, 16-25, 2017 | 29 | 2017 |
| Financing and reimbursement models for personalised medicine: a systematic review to identify current models and future options R Koleva-Kolarova, J Buchanan, H Vellekoop, S Huygens, M Versteegh, ... Applied Health Economics and Health Policy 20 (4), 501-524, 2022 | 25 | 2022 |
| The net benefit of personalized medicine: a systematic literature review and regression analysis H Vellekoop, M Versteegh, S Huygens, IC Ramos, L Szilberhorn, T Zelei, ... Value in Health 25 (8), 1428-1438, 2022 | 20 | 2022 |
| A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening RG Koleva-Kolarova, AM Daszczuk, C de Jonge, MKA Hantash, ZZ Zhan, ... Maturitas 109, 81-88, 2018 | 19 | 2018 |
| Cost-effectiveness analysis of treating patients with NTRK-positive cancer with the histology-independent therapy entrectinib S Huygens, H Vellekoop, M Versteegh, I Santi, L Szilberhorn, T Zelei, ... Value in Health 26 (2), 193-203, 2023 | 9 | 2023 |
| Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients A Tsiachristas, G Vallance, R Koleva-Kolarova, H Taylor, L Solomons, ... BMC cancer 22 (1), 458, 2022 | 9 | 2022 |
| To screen or not to screen for breast cancer? How do modelling studies answer the question? RG Koleva-Kolarova, Z Zhan, MJW Greuter, TL Feenstra, GH De Bock Current Oncology 22 (5), 380-382, 2015 | 8 | 2015 |
| Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19· 67 million people and evaluation of model … W Liao, CAC Coupland, J Burchardt, DR Baldwin, F Gleeson, D Baldwin, ... The Lancet Respiratory Medicine 11 (8), 685-697, 2023 | 4 | 2023 |
| Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK R Koleva-Kolarova, H Vellekoop, S Huygens, M Versteegh, MR Mölken, ... Personalized Medicine 20 (4), 339-355, 2023 | 4 | 2023 |
| Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations KK Lim, R Koleva-Kolarova, P Chowienczyk, CDA Wolfe, J Fox-Rushby The Pharmacogenomics Journal 21 (6), 625-637, 2021 | 4 | 2021 |
| Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation R Koleva-Kolarova, L Szilberhorn, T Zelei, H Vellekoop, B Nagy, ... Personalized Medicine 20 (4), 305-319, 2023 | 2 | 2023 |
| Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems R Koleva-Kolarova, H Vellekoop, S Huygens, M Versteegh, MR Mölken, ... Personalized Medicine 20 (4), 357-374, 2023 | 2 | 2023 |
| A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations KK Lim, R Koleva-Kolarova, J Fox-Rushby PharmacoEconomics 40 (10), 989-1003, 2022 | 2 | 2022 |
| Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies B Nagy, T Zelei, H Vellekoop, S Huygens, M Versteegh, MR Mölken, ... Personalized Medicine 20 (4), 401-411, 2023 | 1 | 2023 |
| Cost–effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young G Kovács, D Nagy, L Szilberhorn, T Zelei, Z Gaál, H Vellekoop, ... Personalized Medicine 20 (4), 375-385, 2023 | 1 | 2023 |
Truuske (G.H.) de BockHoogleraar Oncologische Epidemiologie UMCGVerified email at umcg.nl
